[
    {
        "Header Number": "N/A",
        "Title": "TABLE OF CONTENTS",
        "Content": "PAGELIST OF ABBREVIATIONS.............................................................................................31.DOCUMENT HISTORY............................................................................................42.STUDY DESIGN ......................................................................................................43.OBJECTIVES...........................................................................................................94.ENDPOINTS ............................................................................................................95.STUDY POPULATION .............................................................................................96.STATISTICAL METHODS......................................................................................106.1.1.Analysis of demographics ............................................................106.1.2.Descriptive analysis of clinical management ................................107.STATISTICAL CALCULATIONS ............................................................................117.1.Derived and transformed data.....................................................................117.2.Data presentation description .....................................................................128.CONDUCT OF ANALYSES....................................................................................128.1.Sequence of analyses.................................................................................128.2.Statistical considerations for interim analyses.............................................129.CHANGES FROM PLANNED ANALYSES.............................................................1210. REFERENCES.......................................................................................................13 CONFIDENTIAL113617 (HPV-062 EXT:015)Report Final314-MAR-2018 CONFIDENTIAL113617 (HPV-062 EXT:015)Report Finalcd4e50a685e7e4c06b41e9af17bf5ef85f79e54049714-MAR-2018PPDStatistical Analysis PlanStudy alias & e-track number(s): HPV-062 EXT:015 (113617)FORM-9000026972-01 Statistical Analysis Plan TemplateEffective date: 01 June 2014GSK SOP Reference: SOP-9000026972Form Owner: VVHS Biometrics, 01June2014Page 3 of 13",
        "Sub-sections": []
    },
    {
        "Header Number": "N/A",
        "Title": "LIST OF ABBREVIATIONS",
        "Content": "AEAdverse eventAGCAtypical glandular cellsASCCPAmerican Society for Colposcopy and Cervical PathologyASC-USAtypical squamous cells of undetermined significanceASC-HAtypical squamous cells cannot exclude HSILCARS Computer Aided for Regulatory SubmissionCIConfidence IntervalEli TypeInternal GSK database code for type of elimination codeGSKGlaxoSmithKlineHCIIHybrid Capture IIHPVHuman papillomavirusHSILHigh grade squamous intraepithelial lesionLLLower Limit of the confidence intervalLSILLow grade squamous intraepithelial lesionSAESerious adverse eventSAPStatistical Analysis PlanSDStandard DeviationSDDSAS Drug developmentULUpper Limit of the confidence interval CONFIDENTIAL113617 (HPV-062 EXT:015)Report Final414-MAR-2018 CONFIDENTIAL113617 (HPV-062 EXT:015)Report Finalcd4e50a685e7e4c06b41e9af17bf5ef85f79e54049814-MAR-2018PPD",
        "Sub-sections": []
    },
    {
        "Header Number": "1.",
        "Title": "DOCUMENT HISTORY",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "2.",
        "Title": "STUDY DESIGN",
        "Content": "Statistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 5 of 13\n\uf0b7\nTreatment groups: One study group consisting of a subset of HPV-015 subjects \nwho at their concluding HPV-015 study visit:\n\uf0b7\ndisplayed normal cervical cytology but tested positive for oncogenic HPV \ninfection \n\uf0b7\nwere pregnant so that no cervical sample could be collected at that visit\nThe study eligibility algorithm is presented in Figure 2.\nFigure 2\nHPV-062 EXT:015 study eligibility algorithm\n\uf0b7\nVaccination schedule(s): None.\n\uf0b7\nControl: None.\n\uf0b7\nType of study: Gynaecological follow-up extension study of a subset of HPV-015 \nstudy subjects.\n\uf0b7\nData collection: Remote Data Entry (RDE).\n\uf0b7\nDuration of the study: Maximum of four years for each subject.\n\uf0b7\nStudy visits per subject: Up to four scheduled visits at approximately Months 12, \n24, 36 and 48 after each subject\u2019s concluding HPV-015 study visit. \nSubjects are eligible to join the study at any visit.\n\uf0b7\nStudy procedures:\nSubjects will enter the study approximately one year after their HPV-015 concluding \nvisit. Annual visits will be scheduled for a maximum study duration of \napproximately four years.\nNo cervical sample collected \ndue to pregnancy\nHPV-015 concluding \nvisit completed\nCervical cytology \ntest normal\nCervical cytology \ntest abnormal\nOncogenic HPV \nDNA test (PCR) \ntest positive\nOncogenic HPV \nDNA test (PCR) \ntest negative\nHPV-015 colposcopy \nand, if required, \ntreatment \nNo follow-up\nHPV-015 study end\nEnrol in HPV-062\nHPV-015 study end\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n6\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n500\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 6 of 13\nAt each visit, a gynaecological examination will be performed and cervical liquid-\nbased cytology samples will be collected for cervical cytology examination and \noncogenic HPV DNA testing, if the cytology reading is normal or ASCUS.\nThe presence of oncogenic HPV infection will be determined by the Hybrid \nCapture\u00ae II (HCII) test, which detects HPV DNA types 16, 18, 31, 33, 35, 39, 45, \n51, 52, 56, 58, 59 and 68 [Vernick, 2003, Digene Corporation 2002]. Cervical \ncytology examination will be performed using the ThinPrep\u00aePap test.\nContinued study participation as well as further referral/treatment will be based on \nthe test results from each visit, and will be aligned with the clinical management \nalgorithm which is aligned with the 2009 American Society for Colposcopy and \nCervical Pathology (ASCCP) guidelines for use of HPV DNA testing as an adjunct \nto cytology for cervical cancer screening in women 30 years or older.\nThe following clinical management algorithm will be applied, refer to Figure 3.\n\uf0b7\nSubjects with normal cervical cytology and who are oncogenic HPV DNA \nnegative, will end their participation in the study.\n\uf0b7\nSubjects with normal cervical cytology, but who are oncogenic HPV DNA \npositive in one single test, will be asked to return at the next study visit.\nThis outcome will only be applicable to subjects who were pregnant at their \nconcluding HPV-015 study visit so that no cervical sample could be collected at \nthat visit.\n\uf0b7\nSubjects with normal cervical cytology, but who are oncogenic HPV DNA \npositive in two subsequent tests, will be referred to colposcopy. The result of the \nsubjects\u2019 last HPV-015 study visit will be taken into account at Visit 1.\n\uf0b7\nSubjects with a single cervical cytology reading of \uf0b3ASC-US (atypical \nsquamous cells of undetermined significance) and positive for oncogenic HPV \nDNA will be referred to colposcopy.\n\uf0b7\nSubjects with a single cervical cytology reading of \uf0b3LSIL (low grade squamous \nintraepithelial lesion) will be referred to colposcopy.\nPlease note that a missing result for HCII will be managed as oncogenic HPV \npositive.\nIn case of referral for colposcopy, the post-colposcopy follow-up strategies are:\n\uf0b7\nIf no lesion is detected or the detected lesion does not require any treatment, \nsubjects will be asked to return at the next study visit.\n\uf0b7\nIf a lesion that requires treatment is detected, the subject should be referred to \ntreatment according to local medical practice. Any further management \nfollowing local cervical therapy for cervical lesions will be handled according to \n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n7\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n501\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 7 of 13\nlocal medical practice within the local health care system. After treatment, the \nsubject\u2019s participation in the study will end.\nAs management algorithms cannot define every clinical situation, it is the \ninvestigator\u2019s (or his/her designee\u2019s) responsibility to exercise appropriate clinical \njudgement in the medical management of each individual case.\nOnce their study participation ends, all subjects should be referred to their local \nhealth care system.\nSubjects who have not developed cervical lesions by the end of the study, but who \nare still positive for oncogenic HPV infection, should be informed of the potential \nrisks of being positive for oncogenic HPV DNA, and the importance of continued \nfollow-up.\nFigure 3\nClinical management algorithm \nHPVDNA test (HCII) = Hybrid Capture\u00ae II test detecting HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.\nSpecimens will be reported as \u201cQuantity Not Sufficient\u201d (QNS) in the case where there is an inadequate amount of cells for HCII and \npreferentially, a repeat sample will be collected. Missing HCII test results should be managed as oncogenic HPV positive\n* = The result of the subject\u2019s concluding HPV-015 study visit will be taken into account. Subjects who were pregnant at that visit so \nthat no cervical sample could be collected, and who display normal cytology but are positive for oncogenic HPV DNA at Visit 1, will \nreturn for the next study visit.\nHPV-062 Visit1, 2, 3 and 4\nCervical cytology examinationand oncogenic HPV test (HCII), if applicable$\nNormal cervical cytology /\nHCII negative\nOR\nASC-US / HCIInegative\nNormal cervical cytology / \nHCII positive\n\u2265ASC-US / HCII positive\nOR\n\u2265LSIL \nFirst time: nextstudyvisit\nSecond time: colposcopy *\nColposcopy **\nNo lesion\nOR\nNo lesionrequiringtreatment\nLesionrequiringtreatment\nTreatmentaccording\nto local practice\nStudyconclusion\nReturn to nextstudyvisit\nAfter Visit4\nStudyconclusion\nStudyconclusion\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n8\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n502\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 8 of 13\n** = Colposcopy and/or colposcopy-directed biopsies will be performed according to local medical practice.\n$ = Oncogenic HPV tests (HCII) will only be performed on normal and ASCUS cytological samples.\n\uf0b7\nStudy visit activities and gynaecological follow-up reporting\n\uf0b7\nGynaecological examination at Visit 1, Visit 2, Visit 3 and Visit 4.\n\uf0b7\nCollection of cervical liquid-based cytology samples at Visit 1, Visit 2, Visit 3 \nand Visit 4 for cervical cytology examination and oncogenic HPV DNA testing, \nif the cytology reading is normal or ASCUS. \n\uf0b7\nReferral to colposcopy according to protocol clinical management algorithm, if \nrequired.\n\uf0b7\nConduct of colposcopy, colposcopy directed biopsies and local cervical therapy \naccording to local medical practice, if required.\n\uf0b7\nRecording of colposcopic referral according to management algorithm, if \nrequired.\n\uf0b7\nRecording of treatment referrals according to local medical practice, if required.\n\uf0b7\nSafety reporting:\n\uf0b7\nAll fatal SAEs will be reported.\n\uf0b7\nAll SAEs assessed as being possibly related to study participation will be \nreported.\n\uf0b7\nAll SAEs assessed as being possibly related to a concurrent GSK medication \nwill be reported.\n\uf0b7\nWithdrawal from the study due to adverse events (AEs) or SAEs will be \nreported.\nNo other AEs or SAEs for HPV-015 study subjects will be reported in this study. AEs \nand SAEs related to the vaccine administrated in the HPV-015 trial should be reported as \npart of the HPV-015 study, as described in the HPV-015 study protocol. \nThe following group names will be used for the statistical analyses:\nGroup order in tables\nGroup label in tables\nGroup definition for footnote\n1\nHPV-062 study subjects\nHPV-015 study subjects enrolled in HPV-\n062 who displayed normal cervical \ncytology but tested positive for oncogenic \nHPV infection at their concluding HPV-\n015 study visit. or who were pregnant at \ntheir concluding study visit were not able \nto provide a cervical sample\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n9\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n503\n14-MAR-2018\nPPD\n",
        "Sub-sections": []
    },
    {
        "Header Number": "3.",
        "Title": "OBJECTIVES",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "4.",
        "Title": "ENDPOINTS",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "5.",
        "Title": "STUDY POPULATION",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "6.",
        "Title": "STATISTICAL METHODS",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "6.1.1.",
                "Title": "Analysis of demographics",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "6.1.2.",
                "Title": "Descriptive analysis of clinical management",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "7.",
        "Title": "STATISTICAL CALCULATIONS",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "7.1.",
                "Title": "Derived and transformed data",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "7.2.",
                "Title": "Data presentation description",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "8.",
        "Title": "CONDUCT OF ANALYSES",
        "Content": "",
        "Sub-sections": [
            {
                "Header Number": "8.1.",
                "Title": "Sequence of analyses",
                "Content": "",
                "Sub-sections": []
            },
            {
                "Header Number": "8.2.",
                "Title": "Statistical considerations for interim analyses",
                "Content": "",
                "Sub-sections": []
            }
        ]
    },
    {
        "Header Number": "9.",
        "Title": "CHANGES FROM PLANNED ANALYSES",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "10.",
        "Title": "REFERENCES",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "N/A",
        "Title": "Figure 1 Study visits and study procedures",
        "Content": "",
        "Sub-sections": []
    },
    {
        "Header Number": "N/A",
        "Title": "Figure 2  HPV-062 EXT:015 study eligibility algorithm",
        "Content": "Statistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 6 of 13\nAt each visit, a gynaecological examination will be performed and cervical liquid-\nbased cytology samples will be collected for cervical cytology examination and \noncogenic HPV DNA testing, if the cytology reading is normal or ASCUS.\nThe presence of oncogenic HPV infection will be determined by the Hybrid \nCapture\u00ae II (HCII) test, which detects HPV DNA types 16, 18, 31, 33, 35, 39, 45, \n51, 52, 56, 58, 59 and 68 [Vernick, 2003, Digene Corporation 2002]. Cervical \ncytology examination will be performed using the ThinPrep\u00aePap test.\nContinued study participation as well as further referral/treatment will be based on \nthe test results from each visit, and will be aligned with the clinical management \nalgorithm which is aligned with the 2009 American Society for Colposcopy and \nCervical Pathology (ASCCP) guidelines for use of HPV DNA testing as an adjunct \nto cytology for cervical cancer screening in women 30 years or older.\nThe following clinical management algorithm will be applied, refer to Figure 3.\n\uf0b7\nSubjects with normal cervical cytology and who are oncogenic HPV DNA \nnegative, will end their participation in the study.\n\uf0b7\nSubjects with normal cervical cytology, but who are oncogenic HPV DNA \npositive in one single test, will be asked to return at the next study visit.\nThis outcome will only be applicable to subjects who were pregnant at their \nconcluding HPV-015 study visit so that no cervical sample could be collected at \nthat visit.\n\uf0b7\nSubjects with normal cervical cytology, but who are oncogenic HPV DNA \npositive in two subsequent tests, will be referred to colposcopy. The result of the \nsubjects\u2019 last HPV-015 study visit will be taken into account at Visit 1.\n\uf0b7\nSubjects with a single cervical cytology reading of \uf0b3ASC-US (atypical \nsquamous cells of undetermined significance) and positive for oncogenic HPV \nDNA will be referred to colposcopy.\n\uf0b7\nSubjects with a single cervical cytology reading of \uf0b3LSIL (low grade squamous \nintraepithelial lesion) will be referred to colposcopy.\nPlease note that a missing result for HCII will be managed as oncogenic HPV \npositive.\nIn case of referral for colposcopy, the post-colposcopy follow-up strategies are:\n\uf0b7\nIf no lesion is detected or the detected lesion does not require any treatment, \nsubjects will be asked to return at the next study visit.\n\uf0b7\nIf a lesion that requires treatment is detected, the subject should be referred to \ntreatment according to local medical practice. Any further management \nfollowing local cervical therapy for cervical lesions will be handled according to \n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n7\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n501\n14-MAR-2018\nPPD\n",
        "Sub-sections": []
    },
    {
        "Header Number": "N/A",
        "Title": "Figure 3 Clinical management algorithm",
        "Content": "Statistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 8 of 13\n** = Colposcopy and/or colposcopy-directed biopsies will be performed according to local medical practice.\n$ = Oncogenic HPV tests (HCII) will only be performed on normal and ASCUS cytological samples.\n\uf0b7\nStudy visit activities and gynaecological follow-up reporting\n\uf0b7\nGynaecological examination at Visit 1, Visit 2, Visit 3 and Visit 4.\n\uf0b7\nCollection of cervical liquid-based cytology samples at Visit 1, Visit 2, Visit 3 \nand Visit 4 for cervical cytology examination and oncogenic HPV DNA testing, \nif the cytology reading is normal or ASCUS. \n\uf0b7\nReferral to colposcopy according to protocol clinical management algorithm, if \nrequired.\n\uf0b7\nConduct of colposcopy, colposcopy directed biopsies and local cervical therapy \naccording to local medical practice, if required.\n\uf0b7\nRecording of colposcopic referral according to management algorithm, if \nrequired.\n\uf0b7\nRecording of treatment referrals according to local medical practice, if required.\n\uf0b7\nSafety reporting:\n\uf0b7\nAll fatal SAEs will be reported.\n\uf0b7\nAll SAEs assessed as being possibly related to study participation will be \nreported.\n\uf0b7\nAll SAEs assessed as being possibly related to a concurrent GSK medication \nwill be reported.\n\uf0b7\nWithdrawal from the study due to adverse events (AEs) or SAEs will be \nreported.\nNo other AEs or SAEs for HPV-015 study subjects will be reported in this study. AEs \nand SAEs related to the vaccine administrated in the HPV-015 trial should be reported as \npart of the HPV-015 study, as described in the HPV-015 study protocol. \nThe following group names will be used for the statistical analyses:\nGroup order in tables\nGroup label in tables\nGroup definition for footnote\n1\nHPV-062 study subjects\nHPV-015 study subjects enrolled in HPV-\n062 who displayed normal cervical \ncytology but tested positive for oncogenic \nHPV infection at their concluding HPV-\n015 study visit. or who were pregnant at \ntheir concluding study visit were not able \nto provide a cervical sample\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n9\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n503\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 9 of 13\n3.\nOBJECTIVES\n\uf0b7\nTo provide clinical management and, if required, treatment to subjects who at their \nconcluding HPV-015 study visit displayed normal cervical cytology but tested \npositive for oncogenic HPV infection or who were pregnant at their concluding visit \nof the HPV-015 study so that no cervical sample could be collected.\nRefer to Section 4Error! Reference source not found. for the definition of the study \nendpoints.\n4.\nENDPOINTS\n\uf0b7\nOccurrence of positive oncogenic HPV DNA results in cervical samples by HPV \nDNA testing (Hybrid Capture\u00ae II test [HCII]).\n\uf0b7\nOccurrence of cervical cytological abnormalities in cervical samples by ThinPrep\u00ae \nPapTest.\n\uf0b7\nOccurrence of referral to colposcopy.\n\uf0b7\nOccurrence of referral to treatment.\n5.\nSTUDY POPULATION\nThe study population will contain a subset of HPV-015 study enrolled in HPV-062 study\n\uf0b7\nSubjects who displayed normal cervical cytology but tested positive for \noncogenic HPV infection at their concluding HPV-015 study visit. \nor\n\uf0b7\nSubjects who were pregnant at their concluding HPV-015 study visit were not \nable to provide a cervical sample.\nHPV-062 -Total cohort\nThe HPV-062 cohort includes the HPV-015 subjects \n-\nwho conclude their participation in the HPV-015 study at Visit 9, Visit 11 or at \nthe last study visit in HPV-015 study displayed normal cervical cytology but \ntested positive for oncogenic HPV infection \nor \n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n10\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n504\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 10 of 13\n-\nwho were pregnant during HPV-015 study so that  no cervical sample could be \ncollected  at that visit.\n-\nwho attend any visit in this study.\nThe list of applicable elimination codes for this cohort \nCohort\nElimination codes\nEli Type\nHPV-062 -Total cohort\n900,1500\nMA\nMA: Main analysis\n6.\nSTATISTICAL METHODS\nThe analysis will be performed on the HPV-062 Total cohort\n6.1.1.\nAnalysis of demographics\nDemographic characteristics (age, race and gender), withdrawal status will be \nsummarised using descriptive statistics:\nAge: Age of a subject is computed by considering the date of birth and date of the first \nvisit in this study for that subject. Age of a subject was computed as the time interval \nbetween two dates in specified time unit. \n\uf0b7\nFrequency tables will be generated for categorical variable such as race and gender.\n\uf0b7\nMean, median, standard deviation will be provided for continuous data such as age. \nThe distribution of eligible subjects among the study sites will be tabulated.\n6.1.2.\nDescriptive analysis of clinical management\nFor each visit and overall:\n\uf0b7\nResults of oncogenic HPV DNA tests.\n\uf0b7\nResults of cervical cytology tests.\n\uf0b7\nReferrals to colposcopy, if required.\n\uf0b7\nReferrals to treatment according to local medical practice, if required.\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n11\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n505\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 11 of 13\n7.\nSTATISTICAL CALCULATIONS\n7.1.\nDerived and transformed data\nAll CI computed will be two-sided 95% CI.\nThe following categories for cervical cytology reading will be specified:\n\uf0b7\nNegative for intraepithelial lesion or malignancy (negative).\n\uf0b7\nNegative/HCII negative (Normal/oncogenic HPV negative)\n\uf0b7\nNegative/HCII positive (Normal/oncogenic HPV positive).\n\uf0b7\nNegative/HCII quantity not sufficient (Normal/QNS).\n\uf0b7\nUnsatisfactory.\n\uf0b7\nAtypical squamous cells of undetermined significance (ASC-US).\n\uf0b7\nASC-US/HCII negative (ASC-US/oncogenic HPV negative)\n\uf0b7\nASC-US/HCII positive (ASC-US/oncogenic HPV positive).\n\uf0b7\nASC-US/HCII quantity not sufficient (ASC-US/QNS).\n\uf0b7\nAtypical squamous cells cannot exclude HSIL (ASC-H).\n\uf0b7\nLow-grade squamous intraepithelial lesion (LSIL).\n\uf0b7\nHigh-grade squamous intraepithelial lesion (HSIL).\n\uf0b7\nAtypical glandular cells (AGC).\n\uf0b7\nInvasive malignancy.\nHandling of missing data:\nDemography\nFor a given subject and a given demographic variable, missing measurement will not be \nreplaced. Therefore, analysis of demography will exclude subjects with missing \nmeasurements.\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n12\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n506\n14-MAR-2018\nPPD\nStatistical Analysis Plan\nStudy alias & e-track number(s): HPV-062 EXT:015 (113617)\nFORM-9000026972-01 Statistical Analysis Plan Template\nEffective date: 01 June 2014\nGSK SOP Reference: SOP-9000026972\nForm Owner: VVHS Biometrics, \n01June2014\nPage 12 of 13\n7.2.\nData presentation description\nThe following decimal description will be used for the demography and safety analyses.\nDisplay Table\nParameters\nNumber of decimal digits\nAll summaries\n% of count, including LL & UL of CI\n1\nDemographic characteristics\nMean, median age\n1\nDemographic characteristics\nSD (age)\n1\n8.\nCONDUCT OF ANALYSES\nAny deviation(s) or change(s) from the original statistical plan outlined in this protocol \nwill be described and justified in the final study report.\n8.1.\nSequence of analyses\nThe final analyses will be conducted when all data are available. This analysis will \ninclude the final analysis of Demography and safety. These analyses will be the basis of a \nClinical Study Report and will be made available to the investigator(s).\nDescription\nAnalysis ID \n(SDD & CARS sub-folder)\nFinal Analysis\nE1_01\n8.2.\nStatistical considerations for interim analyses\nNo interim analysis is planned for this study.\n9.\nCHANGES FROM PLANNED ANALYSES\nSince SAE is not the endpoints of study protocol, following analysis related to SAE will \nnot be generated\n\uf0b7\nAll fatal SAEs occurring throughout the study period.\n\uf0b7\nAll SAEs assessed as being possibly related to study participation occurring \nthroughout the study period.\n\uf0b7\nAll SAEs assessed as being possibly related to GSK products occurring throughout \nthe study period.\n\uf0b7\nWithdrawal from the study due to AEs or SAEs\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\n13\n14-MAR-2018\n \nCONFIDENTIAL\n113617 (HPV-062 EXT:015)\nReport Final\ncd4e50a685e7e4c06b41e9af17bf5ef85f79e540\n507\n14-MAR-2018\nPPD\n",
        "Sub-sections": []
    }
]